Masdil Retard

Diltiazem Hydrochloride, the active ingredient in Masdil Retard, is a calcium channel blocker presented as an extended‑release tablet for oral use. It helps control high blood pressure and relieves chest pain caused by chronic stable angina, and is indicated for patients with coronary artery disease.

GNH USA supplies Masdil Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing EU‑origin quality for global markets. All batches meet EU pharmacopoeial standards and are shipped under controlled conditions to maintain product integrity.

Diltiazem Hydrochloride is a calcium channel blocker used to manage cardiovascular conditions.

Hypertension: lowers systemic vascular resistance and cardiac workload, resulting in sustained reduction of arterial blood pressure.

Chronic stable angina: dilates coronary arteries and reduces myocardial oxygen demand, decreasing the frequency and severity of angina episodes.

Coronary artery disease: improves coronary blood flow and limits ischemic episodes, supporting overall cardiac perfusion.

Diltiazem Hydrochloride may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate. - Peripheral edema: swelling of ankles. - Dizziness: light‑headedness on standing. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Bradycardia: markedly reduced heart rate. - Heart block: AV conduction disturbances. - Severe hypotension: abrupt drop in blood pressure.

When prescribing Diltiazem Hydrochloride, clinicians should consider several precautionary measures to ensure safe use.

- Cardiovascular assessment: evaluate for existing heart block or severe heart failure before initiation. - Concomitant beta‑blockers: avoid combined use unless closely monitored due to risk of excessive bradycardia. - Liver impairment: dose may need adjustment in patients with hepatic dysfunction. - Pregnancy: use only if potential benefit justifies potential risk, as safety data are limited. - Elderly patients: start at lower dose and monitor for hypotension and dizziness. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Diltiazem Hydrochloride interacts with several medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase diltiazem plasma levels. - Beta‑blockers (e.g., metoprolol) combined with diltiazem: can cause severe bradycardia or AV block. - Digoxin: diltiazem can raise digoxin concentrations, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors, diuretics): additive blood pressure lowering effect. - Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): may increase statin exposure, raising myopathy risk. - Anticonvulsants (e.g., carbamazepine): may reduce diltiazem effectiveness.